|
|
|
| home > ict > Spring 2009 |
|
|
 PUBLICATIONS |
International Clinical Trials |
|
|
|
|
| At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. ICT provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of pharmaceuticals, take a look below at the range of articles featured in this issue of ICT. |
 |
| |
|
|
|
| The effects of the recession and the prospect of thinning pipelines are major concerns for pharmaceutical companies; Sriram V of Frost & Sullivan discusses the long-term outlook for CROs. |
|
|
| Nicola Murgatroyd at Phlexglobal examines the importance of the role of clinical research associate and looks at the reasons why the industry is facing a shortage of candidates. |
|
|
| The increasing number of clinical trials being performed in developing economies has made high quality translation more important than ever, argues Mimi Maeda-Nye of TJC Global. |
|
|
|
| James Trammel at i3 Statprobe underlines the value of adaptive randomisation, explaining the methods that can be used to guarantee the validity of statistical conclusions. |
|
|
| In the context of the dramatic increase in the number of late-phase clinical trials worldwide, Kate Trainor of PAREXEL International looks at how the right technology can make a major difference in Phases IIIb and IV. |
|
|
| Tim Davis of Exco InTouch reflects on the immense popularity of SMS communication, and explains how text messaging technology can increase recruitment, retention and compliance in clinical trials |
|
|
| A well-integrated laboratory information management system, with the flexibility to work with an adaptive trial design, greatly increases the ability to get specimen handling, testing and reporting 'right first time', says Ed Krasovec of Starlims. |
|
|
|
|
| For clinical research conducted in developing countries, ethical concerns are a particularly salient issue. Harald Schmidt of the Nuffield Council of Bioethics and Peter G Smith of the London School of Hygiene & Tropical Medicine review the 2008 Declaration of Helsinki. |
|
|
|
| In light of the tough economic times, Richard N Williams of INC Research looks at how value can be maximised and drug development accelerated by embracing fresh regulatory initiatives. |
|
|
|
Beata Paluchowska of Omnicare Clinical Research describes how the challenges involved in clinical trials for cancer drugs can be overcome by means of collaboration with oncology communities and experts from different fields. |
|
|
| Jan Vertommon at Capsugel explains how enhanced bioavailability can improve the quality of data obtained from first-in-human clinical trials and evaluates the ways in which this can be achieved. |
|
|
| Nick Charles of Mayo Clinic presents a case study on the benefits of running a collaborative trial for Graves' ophthalmopathy. |
|
|
|
|
| Jeffrey Litwin of ERT Inc looks at the critical role of central core labs in performing thorough ECG analysis. |
|
|
| Nick Townsend of LabWare explains why configurable LIMS with purpose-built modules are an asset for clinical trials, and looks at the options available when choosing a LIMS product. |
|
|
| As the focus of clinical trial activity shifts towards Asia, Robert Scott-Edwards of ICON Central Laboratories investigates the opportunities and challenges in India. |
|
|
| Geraint Thomas at Laminar Medica outlines the factors to consider when developing a passives cooling system which offers protection while meeting all relevant laws, regulations and guidelines. |
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita
MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >> |
|
 |
White Papers |
 |
|
 |
Industry Events |
 |
Nordic Life Science Days 10/12 September 2019
10-12 September 2019, Malmo Sweden
Nordic Life Science Days is the largest Nordic partnering conference for the global Life
Science industry.
Bringing together the best talents in Life Science, offering amazing networking and
partnering opportunities, providing inputs and content on the most recent trends.
Nordic Life Science Days attracts leading decision makers from the Life Science sector,
not only from biotech, pharma and medtech but also from finances, research, policy and
regulatory authorities.
More info >> |
|
|
